Tom joined Brandon Capital Partners in 2015.
Tom is Co-founder and Executive Chairman of Grey Wolf Therapeutics. Tom is also Co-Founder and CEO of Molecule 2 Medicine, a UK based consulting firm. His previous positions include Vice President of Drug Development at Starpharma, Australia. Tom undertook his postdoctoral training at the University of Oxford.
Tom is currently a director of Kea Therapeutics. Tom was former President and CEO of Spinifex Pharmaceuticals (acquired by Novartis in 2015).
Tom has a Bachelor of Science (Honours) from Monash University and a PhD from Monash University.